Cartesian Therapeutics, Inc. Retained Earnings
Cartesian Therapeutics, Inc. (RNAC) had Retained Earnings of -$845.79 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$845.79M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$861.55M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$822.37M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$729.80M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$845.79M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$861.55M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | -$822.37M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$729.80M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$693.89M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$709.78M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$692.07M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$681.82M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$657.63M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$671.47M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | -$614.65M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$436.99M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$427.99M 10-Q · filed 2023-08-17 | |
| 2023-03-31 | -$416.60M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$394.94M 10-K · filed 2024-03-07 | |
| 2022-09-30 | -$400.83M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | -$392.94M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$401.54M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$430.32M 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$442.56M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$424.66M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$429.23M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$404.63M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$389.18M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$379.45M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$355.37M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$335.75M 10-K · filed 2021-03-12 | |
| 2019-09-30 | -$320.87M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | -$308.87M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$335.80M 10-Q · filed 2020-05-07 | -$292.48M 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$280.40M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$263.15M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$247.15M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | -$228.36M 10-Q · filed 2018-05-09 | |
| 2018-01-01 | -$215.07M 10-K · filed 2019-03-15 | -$212.47M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$216.90M 10-K · filed 2019-03-15 | |
| 2017-09-30 | -$197.35M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$182.68M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | -$166.71M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | -$151.58M 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$137.49M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$129.76M 10-Q · filed 2016-08-09 | |
| 2015-12-31 | -$111.51M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |